Company profile: Nephros
1.1 - Company Overview
Company description
- Provider of water purification products and pathogen detection systems for medical and commercial markets, including FDA-cleared infection control filters that retain bacteria, viruses, and endotoxins; dialysis water filtration meeting AAMI standards; commercial filters improving taste, odor, and reducing scale without polyphosphates; point-of-use and in-line infection control filters; and water management plan support.
Products and services
- Dialysis Filtration: AAMI-compliant assemblies that purify dialysis water, meeting or exceeding standards while supporting central water systems and portable DI/RO equipment in renal care
- Infection Control Filtration: FDA-cleared filters engineered to retain bacteria, viruses, and endotoxins for use in healthcare facilities, delivering pathogen retention across clinical water applications
- Water Management Plan Support: Audit-based services performing water system evaluations and audits to help facilities meet infection control compliance requirements and mitigate patient risk
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nephros
Renibus Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics to prevent and treat kidney disease, with RBT-1 (single-dose IV before elective cardiac surgery to reduce post-operative complications; Phase 3), Veverimer (oral hydrochloric acid binder for orphan diseases), RBT-3 (iron nanoparticle to restore iron and improve blood product use in cardiac surgery and ER), RBT-9 (anti-inflammatory/antioxidant for COVID-19), and RBT-2 (oral antioxidant/antifibrotic to delay CKD).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renibus Therapeutics company profile →
Renal Solutions
HQ: United States
Website
- Description: Provider of dialysis products and services, focused on their development. Founded in 2000 and based in Warrendale, Pennsylvania; acquired by Fresenius Medical Care in November 2007.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Renal Solutions company profile →
Allena Pharmaceuticals
HQ: United States
Website
- Description: Provider of non-systemic protein therapeutics to treat metabolic and orphan diseases, engaged in development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allena Pharmaceuticals company profile →
ProKidney
HQ: United States
Website
- Description: Provider of specialized treatment for chronic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProKidney company profile →
Quanta Dialysis Technologies
HQ: United Kingdom
Website
- Description: Provider of advanced haemodialysis systems for use in the home and clinic, focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based, high-performance, compact haemodialysis system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanta Dialysis Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nephros
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nephros
2.2 - Growth funds investing in similar companies to Nephros
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nephros
4.2 - Public trading comparable groups for Nephros
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →